Abdominal Obesity
Conditions
Brief summary
Dose-ranging, randomized, double-blind, vehicle-controlled study
Detailed description
Subject will receive a single injection for each treatment which all 3 test article concentrations and both injection volumes and the vehicle for a total of 7 treatments. Subjects will receive test articles in 3 visits.
Interventions
DRUGSTP705
STP705 composed of 2 siRNA targeting TGF-B1and COX-2 individually.
Sponsors
Sirnaomics
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Masking description
double-blind (investigator & subjects)
Intervention model description
Dose-ranging, double-blind, vehicle-controlled
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
To enter the study, a subject must meet the following criteria: 1. Subject is a male or non-pregnant female 18-65 years of age. 2. Subject has provided written informed consent. 3. Females must be post-menopausal , surgically sterile , or use an effective method of birth control. , Women of childbearing potential (WOCBP) must have a negative urine pregnancy test (UPT) at Visit 1/Screening and Visit 3/Baseline. 4. Subject has agreed to undergo an abdominoplasty procedure, participate in this study, has minimally acceptable adipose tissue in the target areas per protocol, and meets all pre-operative requirements, in the opinion of the investigator and surgeon.
Exclusion criteria
A subject is ineligible to enter the study if he/she meets one or more of the following criteria: 1. Subject is pregnant, lactating, or is planning to become pregnant during the study. 2. Subject has a significant active systemic or localized abdominal infection. 3. Subject has a body mass index (BMI) ≥40. 4. Subject has any medical condition that affects clotting and/or platelet function (e.g., thromboembolic disease, clotting factor deficiencies such as hemophilia). 5. Subject is taking any medications that affect clotting and/or platelet function. This includes, but is not limited to, heparin (including low molecular weight heparin), Coumadin, and factor Xa agents such as apixaban (Eliquis), etc. The use of such medications is precluded up to 7 days prior to Visit 3/Baseline and during the study period. 6. Subject is immunocompromised, in the opinion of the investigator, based on their medical condition (e.g., HIV positive, malignancy), medication use, or other factors. 7. Subject has any clinically significant medical abnormality or chronic disease of the cardiovascular, gastrointestinal, respiratory (e.g., chronic obstructive pulmonary disease), hepatic, or renal systems. This includes conditions (e.g., gastrointestinal surgery) that may interfere with metabolism or excretion. 8. Subject has local skin condition(s) (e.g., rash, scarring, and tattoos) or inadequate injection sites in the region designated for abdominoplasty excision which are inappropriate for participation in the study, in the opinion of the investigator. 9. Subject is currently enrolled in an investigational drug, biologic, or device study. 10. Subject has used an investigational drug, investigational biologic, or investigational device treatment within 30 days prior to first injection of the test article. 11. Subject has a history of sensitivity to any of the ingredients in the test articles (see Section 6.1). 12. Subject is known to be noncompliant or is unlikely to comply with the requirements of the study protocol (e.g., due to alcoholism, drug dependency, mental incapacity) in the opinion of the investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of subjects with presence and severity of the following Local Skin Reactions (LSR): erythema, edema, bruising. | 24 weeks | LSR scale will be used by investigator to assess injection site using a 4-point ordinal scale (0=complete absence, 1=mild, limited involvement, 2= moderate involvement, and 3= severe, extreme involvement) |
| Number of subjects with presence and severity of the following Local Skin Reactions (LSR): pain and stinging/burning. | 24 weeks | LSR scale will be used by subjects to assess injection site using a 4-point ordinal scale (0=complete absence, 1=mild, 2= moderate, and 3= severe) |
| Incidence (severity and causality) of any AEs | 24 weeks | AE's will be classified using CTCAE v.5.0 |
Countries
United States
Outcome results
None listed